Abstract:There are 91 known capsular serotypes of Streptococcus pneumoniae. The nasopharyngeal carriage prevalence of particular serotypes is relatively stable worldwide, but the host and bacterial factors that maintain these patterns are poorly understood. Given the possibility of serotype replacement following vaccination against seven clinically important serotypes, it is increasingly important to understand these factors. We hypothesized that the biochemical structure of the capsular polysaccharides could influence the degree of encapsulation of different serotypes, their susceptibility to killing by neutrophils, and ultimately their success during nasopharyngeal carriage. We sought to measure biological differences among capsular serotypes that may account for epidemiological patterns. Using an in vitro assay with both isogenic capsule-switch variants and clinical carriage isolates, we found an association between increased carriage prevalence and resistance to non-opsonic neutrophil-mediated killing, and serotypes that were resistant to neutrophil-mediated killing tended to be more heavily encapsulated, as determined by FITC-dextran exclusion. Next, we identified a link between polysaccharide structure and carriage prevalence. Significantly, non-vaccine serotypes that have become common in vaccinated populations tend to be those with fewer carbons per repeat unit and low energy expended per repeat unit, suggesting a novel biological principle to explain patterns of serotype replacement. More prevalent serotypes are more heavily encapsulated and more resistant to neutrophil-mediated killing, and these phenotypes are associated with the structure of the capsular polysaccharide, suggesting a direct relationship between polysaccharide biochemistry and the success of a serotype during nasopharyngeal carriage and potentially providing a method for predicting serotype replacement.

Progress on Staphylococcus Aureus Serotype 1 and 2 Capsular Polysaccharides

Advance in Capsular Polysaccharide of Staphylococcus Aureus

Advance in chemical structure of bacterial capsular polysaccharides

Bacterial polysaccharides as vaccines--immunity and chemical characterization

Preparation and preclinical evaluation of two novel Staphylococcus aureus capsular polysaccharide 5 and 8‐fusion protein (Hla‐MntC‐SACOL0723) immunoconjugates

Extraction and Determination of Staphylococcus aureus Capsular Polysaccharide

Synthesis of oligosaccharide fragments of capsular polysaccharide Staphylococcus aureus type 8

Effect of the glycosyltransferases on the capsular polysaccharide synthesis of Streptococcus suis serotype 2

Molecular pathogenesis of the hyaluronic acid capsule of Pasteurella multocida

Chemical Synthesis of Truncated Capsular Oligosaccharide of Serotypes 6C and 6D of Streptococcus pneumoniae with Their Immunological Studies

Progress Toward the Development of a Vaccine Against Streptococcus Suis Capsular Type2

The Effect of Culture Condition on Type 5 Capsular Polysaccharide Production of Staphylococcus Aureus from Diary Cattle

Preparation and immunogenicity of Staphylococcus aureus type 336 polysaccharides conjugated antigen

[Bacterial Capsular Polysaccharide--a Review].

Pneumococcal Capsular Polysaccharide Structure Predicts Serotype Prevalence

Regulative synthesis of capsular polysaccharides in the pathogenesis of Streptococcus suis

Progress Toward the Development of a Vaccine Against Streptococcus suis Capsular Type 2

Studies on Preparation and Immunogenicity of Streptococcus Pneumoniae Type 2 Polysaccharide-Tetanus Toxoid Conjugate Vaccine

Development of a conjugate vaccine against invasive pneumococcal disease based on capsular polysaccharides coupled with PspA/family 1 protein of Streptococcus pneumoniae.

[Comparison of Monosaccharide Composition of Capsular Polysaccharides in Streptococcus Suis Serotype 1, 2, 14 and 1/2].

Genetic analysis of the capsular polysaccharide synthesis locus in 15 Streptococcus suis serotypes.